Abiomed, Inc. (NASDAQ: ABMD) today announced the appointment of Paul Krell to the position of General Manager for its European operations, based in Aachen, Germany. Paul Krell joins Abiomed from ev3 Europe where he most recently served as Vice President, Europe, in the Neurovascular Division. He has more than 14 years of experience in the medical device industry, with a strong cardiac background built during his tenure at Guidant, where Mr. Krell held several management positions, including Country Manager in Germany for Cardiac Surgery Products and European Marketing Manager for Tachyarrhythmia Products.
“Abiomed is fortunate to have Paul Krell join our dedicated team in Europe,” said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. “He has strong operational experience and proven success in our industry. We look forward to his contributions and leadership as we continue to grow our European operations.”
Mr. Krell has demonstrated success penetrating the European markets and driving growth with positions in marketing for Europe and sales management for Germany. Mr. Krell graduated from the Institute for Management Development (IMD) International in Lausanne, Switzerland with an Executive Masters in Business Administration (EMBA) and has a graduate degree in Electrical Engineering from the Technical University in Aachen.
“I am excited to join Abiomed and bring advanced circulatory care to European patients and customers,” commented Krell.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. Abiomed currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000 Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. The Company also developed the AbioCor® Implantable Replacement Heart. In Europe, Abiomed offers the Impella® LP2.5, Impella® LP5.0, Impella® LD, the Impella® RD and an Intra-Aortic Balloon and the iPulse™ console under CE Mark approval. The Impella® 5.0 and 2.5 are investigational devices limited by Federal Law solely to investigational use in the United States. Other Impella devices and the iPulse™ combination console system are not yet available for sale in the United States. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed’s existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Company’s most recently filed quarterly report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
